Oracle Health Sciences has released the Oracle Health Sciences Translational Research Center 3.0, a platform that enables secondary use of electronic health records and omics data to help accelerate biomarker identification for drug discovery, clinical development and translational medicine.

This new release features expanded omics and clinical data models, new user interfaces and workflows for patient stratification and reporting, advanced analytical capabilities that facilitate the discovery of driver mutations and enhanced role-based data access security, ultimately supporting accelerated insight needed to advance personalized medicine.

Oracle approximately doubled the size of the omics and clinical data models to lay a foundation for expanded insight and discovery. The clinical data model now includes more than 70 major tables, up from approximately 35, as well as many new attributes, such as medical encounters, treatment outcomes and patient’s family medical histories. The omics data model features approximately 50 new tables, more than 100 total, which support histology and mutation data from Catalog of Somatic Mutations in Cancer (COSMIC) and Human Gene Mutation Database (HGMD) data, as well as expanded structural variation. With new support for multiple reference genomes, researchers can easily identify, track and analyze changes to a patient’s genome over the disease lifecycle, in addition to comparing it to the reference.

The update also supports Genome Variant Call Format (GVCF), which is critical to bringing genome research to the clinical environment. The new capabilities enable a physician to more easily compare genome regions sequenced for a patient with the applicable reference.

Oracle Health Sciences Translational Research Center includes more than 20 new user interfaces (UIs) and workflows, as well as 30 enhanced UIs that expand concepts available for search and accelerate reporting and post-cohort analysis. The newly introduced collaboration module enables users to share patient stratification criteria and other research findings with another user or a user group, and all of these functions can be achieved via the intuitive UI. Advanced data-level security capabilities enable researches to expand collaboration while supporting the safety of their data.

“The future of personalized medicine rests on our collective ability to rapidly advance secondary use of health information and glean new insight from it. Oracle Health Sciences Translational Research Center is purpose-built for this objective,” said Jonathan Sheldon, Ph.D., global vice president, Oracle Health Sciences. “The latest version of the solution supports many new genotypic and phenotypic analytic capabilities that will speed biomarker discovery and subsequent application in both clinical trials and clinical care settings.”